Dr William Sikov was talking about subtype, genetic subtype, and the response to either bevacizumab neoadjuvant therapy or carboplatin. Complex, a little bit complex, but there seemed to be a signal in some genetic subtypes influencing bevacizumab but not carboplatin. What did you make of all that?
And this might be based on genetic subtype?
Well, what his data suggests is no, it’s just based on clinical information. Triple negative.
So if you’re using carboplatin that’s not important?
Yes, triple negative. Based on that study, again, he saw the benefit on basal-like and non-basal-like, all triple negative which is a clinical definition.